Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company’s web site at www.oncothyreon.com.
- 17 years ago
QualityStocks
Oncothyreon, Inc. (NASDAQ: ONTY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…